Anti-SCN9A/ ETHA/ FEB3B monoclonal antibody

Anti-SCN9A/ ETHA/ FEB3B antibody for FACS & in-vivo assay

Target products collectionGo to SCN9A/SCN9A products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-T12119-Ab-1/ GM-Tg-hg-T12119-Ab-2Anti-Human SCN9A monoclonal antibodyHuman
GM-Tg-rg-T12119-Ab-1/ GM-Tg-rg-T12119-Ab-2Anti-Rat SCN9A monoclonal antibodyRat
GM-Tg-mg-T12119-Ab-1/ GM-Tg-mg-T12119-Ab-2Anti-Mouse SCN9A monoclonal antibodyMouse
GM-Tg-cynog-T12119-Ab-1/ GM-Tg-cynog-T12119-Ab-2Anti-Cynomolgus/ Rhesus macaque SCN9A monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-T12119-Ab-1/ GM-Tg-felg-T12119-Ab-2Anti-Feline SCN9A monoclonal antibodyFeline
GM-Tg-cang-T12119-Ab-1/ GM-Tg-cang-T12119-Ab-2Anti-Canine SCN9A monoclonal antibodyCanine
GM-Tg-bovg-T12119-Ab-1/ GM-Tg-bovg-T12119-Ab-2Anti-Bovine SCN9A monoclonal antibodyBovine
GM-Tg-equg-T12119-Ab-1/ GM-Tg-equg-T12119-Ab-2Anti-Equine SCN9A monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-T12119-Ab-1/ GM-Tg-hg-T12119-Ab-2; GM-Tg-rg-T12119-Ab-1/ GM-Tg-rg-T12119-Ab-2;
GM-Tg-mg-T12119-Ab-1/ GM-Tg-mg-T12119-Ab-2; GM-Tg-cynog-T12119-Ab-1/ GM-Tg-cynog-T12119-Ab-2;
GM-Tg-felg-T12119-Ab-1/ GM-Tg-felg-T12119-Ab-2; GM-Tg-cang-T12119-Ab-1/ GM-Tg-cang-T12119-Ab-2;
GM-Tg-bovg-T12119-Ab-1/ GM-Tg-bovg-T12119-Ab-2; GM-Tg-equg-T12119-Ab-1/ GM-Tg-equg-T12119-Ab-2
Products NameAnti-SCN9A monoclonal antibody
Formatmab
Target NameSCN9A
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody, Therapeutics Target antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-SCN9A benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species SCN9A/ ETHA/ FEB3B VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-T12119
    Target NameSCN9A
    Gene ID6335,20274,78956,574119,100855710,101082841,533065,100052120
    Gene Symbol and SynonymsENACH,ETHA,FEB3B,GEFSP7,HSAN2D,mKIAA4197,Nav1.7,NE-NA,NENA,PN1,Scn2a,SCN9A,SFNP
    Uniprot AccessionQ15858,O08562
    Uniprot Entry NameSCN9A_HUMAN,SCN9A_RAT
    Protein Sub-locationTransmembrane Protein
    CategoryTherapeutics Target
    DiseaseN/A
    Gene EnsemblENSG00000169432
    Target ClassificationIon Channel

    The target: SCN9A, gene name: SCN9A, also named as ETHA, FEB3B, GEFSP7, HSAN2D, NE-NA, NENA, Nav1.7, PN1, SFNP. This gene encodes a voltage-gated sodium channel which plays a significant role in nociception signaling. Mutations in this gene have been associated with primary erythermalgia, channelopathy-associated insensitivity to pain, and paroxysmal extreme pain disorder. [provided by RefSeq, Aug 2009].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.